Drug Profile
ICT 140
Alternative Names: ICT-140Latest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator ImmunoCellular Therapeutics
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Ovarian cancer
Most Recent Events
- 30 Dec 2022 ICT 140 is still in preclinical development for Ovarian cancer in USA (Parenteral)
- 28 May 2020 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral)
- 08 May 2019 ImmunoCellular Therapeutics and Unknown company entered into a asset purchase agreement for ICT 107, ICT 140, ICT 121 and stem-to-T-cell research programme preclinical asset